To make these enhancements, Redmond, Wash.-based Microsoft is acquiring certain assets of Rosetta Biosoftware, a unit of Merck & Co. Inc., Whitehouse Station, N.J.
In addition, Merck, a pharmaceutical company, is establishing a business relationship with Microsoft to help enhance Amalga. Merck also will become an Amalga user. The companies expect to close the deal at the end of June and incorporate the new data in Amalga in early 2010.
Microsoft unveiled the life sciences version of Amalga, targeting the biotechnology and pharmaceutical sectors, in April.
More information is available at microsoft.com.
--Howard Anderson
Be the first to comment on this post using the section below.